What does system sales and leases — revenue mean?

This metric represents the total revenue generated from the direct sale and leasing of robotic surgical systems to healthcare providers. It serves as a primary indicator of market adoption and the expansion of the company's installed base of capital equipment. Growth in this segment reflects the company's ability to successfully place its technology in clinical environments, which typically drives subsequent recurring revenue from disposables and service contracts.

PROCEPT BioRobotics Corporation (PRCT) System sales and leases — Revenue

Screener

Other product segments

Handpieces and other consumables

$55.2M+12.3%

Service

$6.84M+36.1%

Similar metrics at other companies

QBTSSystem sales — Revenue

$255K-75.1%

BNC

BNCEquipment and systems sales — Revenue

$1.54M—

SNWVSystem revenue — Revenue

$2.29M-33.6%

ONTOSystems And Software Revenue — Revenue

$294.04M+37.1%

VAT

VATESystems and consumables revenue — Revenue

$1.6M-48.4%

ECLService and lease sales — Revenue

$966M+11.2%

Other financials

Income statement

See full

Revenue$94.5M+19.3%

Gross profit$62.4M+20.5%

Operating income-$27.4M-23.4%

Net income-$26.9M-37.2%

EPS (diluted)-$0.47-34.3%

Balance sheet

See full

Cash & equivalents$11.4M-96.3%

Total debt$77.5M-2.4%

Total equity$340.1M-11.9%

Total assets$479.4M-6.6%

Cash flow

See full

Operating cash flow-$19.3M-28.0%

CapEx$3.0M+5.4%

Free cash flow-$22.2M-24.4%

Valuation

See full

Market cap$1.1B-30.3%

Enterprise value$1.17B—

P/S3.3×—

Profitability

See full

Gross margin64.2%0.0pp

Operating margin-33.9%+0.5pp

Net margin-32.5%+2.2pp

FCF margin-25.2%-4.6pp

Returns & leverage

See full

Return on equity-30.2%+5.2pp

Debt / equity0.2×0.0×

Current ratio6.5×-2.7×

Where this comes from

Reported directly by PROCEPT BioRobotics Corporation in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: PROCEPT BioRobotics Corporation’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 4:14 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001588978-26-000030

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Revenue	$94,498	$79,182	$177,631	$148,344
Cost of sales	32,119	27,436	61,304	52,437
Gross profit	62,379	51,746	116,327	95,907
Operating expenses:
Research and development	20,101	17,632	41,567	34,034
Selling, general and administrative	69,668	56,303	134,756	111,499
Total operating expenses	89,769	73,935	176,323	145,533
Loss from operations	(27,390)	(22,189)	(59,996)	(49,626)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is PROCEPT BioRobotics Corporation's system sales and leases — revenue?: PROCEPT BioRobotics Corporation (PRCT) reported system sales and leases — revenue of $32.47M in Q2 2026.
What does system sales and leases — revenue mean?: This metric represents the total revenue generated from the direct sale and leasing of robotic surgical systems to healthcare providers. It serves as a primary indicator of market adoption and the expansion of the company's installed base of capital equipment. Growth in this segment reflects the company's ability to successfully place its technology in clinical environments, which typically drives subsequent recurring revenue from disposables and service contracts.